Stock ALPMY ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Market Closed - OTC Markets
Other stock markets
 01:29:59 06/06/2024 am IST 		5-day change 1st Jan Change
10.23 USD +1.69% Intraday chart for Astellas Pharma Inc. +6.01% -14.03%
03/06 US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT
31/05 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab
MT
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date
CI
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos
MT
Malin Corp investee signs agreement with Astellas Pharma
AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024
CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024
CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
CI
Astellas Pharma Inc. Announces Board and Committee Retirements
CI
European Commission Approves Astellas Pharma Label Extension for Xtandi
MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
CI
Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM
AQ
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs
MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
CI
Lupin Launches Mirabegron Extended-Release Tablets in US
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. ALPMY Stock
  5. News Astellas Pharma Inc.